Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05377242 · ClinicalTrials.gov registry record · NA

Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI

A NA study of Gulf War Illness, sponsored by University of Alabama at Birmingham.

Active
Registry status
NA
Development phase
390
Enrollment target
1
Study location

NCT05377242: Active NA study of Gulf War Illness, sponsored by University of Alabama at Birmingham.

NCT05377242 is a NA study of Gulf War Illness that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 390 participants, above the 102-participant average among 14 other Gulf War Illness trials with a reported enrollment target (282% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05377242, a NA study of Gulf War Illness, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
390 participants
Enrollment target
1
Study location

Study Summary

This project's objective is to identify effective treatments for Gulf War Illness (GWI). The project tests three potential treatments: curcumin, stinging nettle, and resveratrol. The project uses a decentralized clinical trial (DCT) design in which individuals can participate from anywhere in the United States. Recruitment efforts will be designed to obtain a geographically and demographically diverse study sample.

Primary Outcome

Veterans Rand 12-Item Health Survey (VR-12) Physical Functioning Score (PFS) will be assessed via an online survey. The PFS will be assessed on a 7-32 point scale, with higher scores indicating better health.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Curcumin
  • DIETARY_SUPPLEMENT Resveratrol
  • DIETARY_SUPPLEMENT Stinging Nettle

Study Locations (1)

Alabama

  • The University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 390 participants
Start Date 2023-05-31
Est. Completion 2026-06-30
Phase NA
University of Alabama at Birmingham

1,160 total trials

What the registry record for NCT05377242 still lists

NCT05377242 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, above the 102-participant average among 14 other Gulf War Illness trials with a reported enrollment target (282% higher).

The record links to 1 condition, with Gulf War Illness appearing as the primary indexed condition, and to 3 interventions - of which Curcumin is the first listed.

NCT05377242 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT05377242 about?

NCT05377242 is a clinical study titled "Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI". This project's objective is to identify effective treatments for Gulf War Illness (GWI). The project tests three potential treatments: curcumin, stinging nettle, and resveratrol. The project uses a decentralized clinical trial (DCT) design in which individuals can participate from anywhere in the Un...

What is the current status of trial NCT05377242?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 390 participants. The study started on 2023-05-31. Estimated completion is 2026-06-30.

What conditions does trial NCT05377242 study?

This clinical trial studies the following conditions: Gulf War Illness.

What interventions are being tested in trial NCT05377242?

The interventions under investigation include: Curcumin (DIETARY_SUPPLEMENT), Resveratrol (DIETARY_SUPPLEMENT), Stinging Nettle (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05377242?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05377242 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gulf War Illness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05377242's enrollment target sits among peer trials

390 1st of 14 higher than 14 of 14 other Gulf War Illness trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gulf War Illness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00397111 · 390 participants

    Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders

  • NCT05335928 · 390 participants · Phase 3

    Abatacept in Immune Checkpoint Inhibitor Myocarditis

  • NCT05445960 · 390 participants · NA

    Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery

  • NCT05997615 · 390 participants · Phase 1

    Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05377242, the US trial registry maintained by the National Library of Medicine. NCT05377242 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.